# US 2025/0377366 A1 · Assessment of chronic liver disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0377366 A1
- Document ID: US20250377366A1
- Status: Published application
- Kind: A1
- Application number: 19/308,547
- Filed: 2025-08-25
- Published: 2025-12-11
- Earliest claimed: 2023-02-23
- Assignees: Roche Diagnostics Operations, Inc.
- Applicants: Roche Diagnostics Operations, Inc.
- Inventors: Konstantin Kroeniger; Magdalena Swiatek-De Lange; David Morgenstern
- Web page: https://patentgrep.com/patent/US20250377366A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 1/48: involving transferase
- G01N 2333/4745: Insulin-like growth factor binding protein
- G01N 2333/5421: IL-8
- G01N 2333/9108: with definite EC number (2.3.2.-)
- G01N 2800/085: Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method for assessing chronic liver disease in a subject, said method comprising (a) determining an amount of the biomarker Insulin-like growth factor-binding protein 3 (IGFBP3) in a sample from said subject; (b) determining an amount of the biomarker gamma-glutamyltransferase (GGT) in said sample; (c) comparing the amounts of the biomarkers determined in steps (a) and (b) to references for said biomarkers and/or calculating a score for assessing chronic liver disease; and (d) assessing chronic liver disease in said subject based on the comparison and/or the calculation made in step (c). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.

## Claims

### Claim 1

A method for assessing chronic liver disease in a subject, said method comprising
(a) determining an amount of the biomarker Insulin-like growth factor-binding protein 3 (IGFBP3) in a sample from said subject;
(b) determining an amount of the biomarker gamma-glutamyltransferase (GGT) in said sample;
(c) comparing the amounts of the biomarkers determined in steps (a) and (b) to references for said biomarkers and/or calculating a score for assessing chronic liver disease; and
(d) assessing chronic liver disease in said subject based on the comparison and/or the calculation made in step (c).

### Claim 2 (depends on 1)

The method of claim 1, wherein said chronic liver disease is liver fibrosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein said assessing comprises diagnosing liver fibrosis, comprises staging chronic liver disease, comprises staging liver fibrosis, comprises differentiating between non-advanced liver fibrosis and advanced liver fibrosis, and/or comprises excluding advanced liver fibrosis.

### Claim 4 (depends on 1)

The method of claim 1, wherein said method is comprised in a method of monitoring chronic liver disease.

### Claim 5 (depends on 1)

The method of claim 1, wherein said method further comprises the steps of determining an amount of the biomarker Interleukin-8 (IL-8), and wherein step (c) comprises comparing the amounts of the three biomarkers determined to references for said biomarkers and/or calculating a score for assessing chronic liver disease.

### Claim 6 (depends on 1)

The method of claim 1 wherein the amount of the biomarker IGFBP3 and optionally the amount of the biomarker IL-8 is/are determined by an immunoassay.

### Claim 7 (depends on 1)

The method of claim 1, wherein the amount of the biomarker GGT is determined by an activity assay.

### Claim 8 (depends on 1)

The method of claim 1, wherein said sample is a bodily fluid sample.

### Claim 9 (depends on 1)

The method of claim 1, wherein said method comprises determining at least one further biomarker.

### Claim 10 (depends on 1)

The method of claim 1, wherein said method comprises further diagnostic steps.

### Claim 11

A computer-implemented method for assessing chronic liver disease in a subject, said method comprising
(A) obtaining an amount of the biomarker Insulin-like growth factor-binding protein 3 (IGFBP3) in a sample from said subject;
(B) obtaining an amount of the biomarker gamma-glutamyltransferase (GGT) in said sample;
(C) comparing the amounts of the biomarkers determined in steps (a) and (b) to references for said biomarkers and/or calculating a score for assessing chronic liver disease; and
(D) assessing chronic liver disease in said subject based on the comparison and/or the calculation made in step (c).

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

A device comprising
(a) at least one measuring unit for determining an amount of a first biomarker being IGFBP3 and an amount of a second biomarker being GGT in a sample of the subject, said at least one measuring unit comprising at least one detection means for the first biomarker and the second biomarker; and
(b) an evaluation unit operably linked to the measuring unit, said evaluation unit comprising a data processor comprising instructions for carrying out a comparison of the amount of the first biomarker and the second biomarker to references and/or for carrying out a calculation of a score for assessing based on the amounts of the biomarkers.

### Claim 15

(canceled)

### Claim 16 (depends on 2)

The method of claim 2, wherein said chronic liver disease is selected from advanced liver fibrosis, advanced liver fibrosis corresponding to METAVIR score stage F3 or F4, and/or cirrhosis.

### Claim 17 (depends on 8)

The method of claim 8, wherein said body fluid sample is selected from a blood sample, a plasma sample, and/or a serum sample.

### Claim 18 (depends on 9)

The method of claim 9, wherein the at least one further biomarker is selected from aspartate aminotransferase, alanine aminotransferase, platelet count, haptoglobin, alpha2-macroglobulin, apolipoprotein A1, bilirubin, cholesterol, hyaluronan, prothrombin index, hepatocyte growth factor (HGF), Tissue inhibitor of metalloproteinases (TIMP), and/or urea.

### Claim 19 (depends on 10)

The method of claim 10, wherein said further diagnostic steps are selected from sonography, magnetic resonance imaging, radiography, transient elastography, and/or determining subject age and/or gender.

### Claim 20 (depends on 1)

A method of detecting a decrease in the amount of the biomarker Insulin-like growth factor-binding protein 3 (IGFBP3) of claim 1 and an increase in the amount of the biomarker gamma-glutamyltransferase (GGT) of claim 1 in a subject, the method comprising:
measuring an amount of IGFBP3 in a sample from said subject;
measuring an amount of GGT in said sample; and
detecting the decrease in the amount of IGFBP3 and the increase in the amount of GGT in the sample of the subject by contacting the sample with a detection agent for IGFBP3 and a detection agent for GGT, wherein the binding between IGFBP3 and the detection agent for IGFBP3 is detected, and wherein the binding between GGT and the detection agent for GGT is detected.

### Claim 21

A method for measuring a panel of biomarkers in a subject suspected to suffer from chronic liver disease or suffering from chronic liver disease, the method comprising:
obtaining a sample from the subject;
determining a measurement for the panel of biomarkers in the sample, wherein the panel comprises the biomarkers Insulin-like growth factor-binding protein 3 (IGFBP3) and gamma-glutamyltransferase (GGT), wherein the measurement comprises determining a level of each of the biomarkers IGFBP3 and GGT in the panel.

### Claim 22 (depends on 20)

The method of claim 20, further comprising:
measuring an amount of the biomarker Interleukin-8 (IL-8) in said sample; and
detecting whether IL-8 is present in said sample by contacting the sample with a detection agent for IL-8, wherein the binding between IL-8 and the detection agent for IL-8 is detected.

### Claim 23 (depends on 21)

The method of claim 21, wherein the panel further comprises the biomarker Interleukin-8 (IL-8), and wherein the measurement further comprises determining a level of the biomarker IL-8 in the panel.
